“MDMA Therapy for PTSD: The Science Behind MAPS Trials and What Comes Next”
MDMA-assisted therapy showed remarkable results in Phase 3 clinical trials for PTSD, with 67% of participants no longer meeting diagnostic criteria after treatment. Here is a clear-eyed look at the science, the session protocol, the FDA timeline, and who might benefit.